UNSPSC 51392207: Indanazoline

This classification denotes an alpha-adrenergic agonist with the molecular formula C12H15N3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L0U38EHD86, chemically known as 1h-imidazol-2-amine, n-(2,3-dihydro-1h-inden-4-yl)-4,5-dihydro- but generally known as indanazoline, which bears US NIH Compound Identifier 65979. European Medicines Agency schedules Indanazoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08166MIG.

UNSPSC 51392207 Indanazoline is a Commodity code that in state and local procurement practice captures naloxone and drug deactivation systems procurement for public health emergency response and community health initiatives. The recent opportunities under this code show purchasing entities acquiring naloxone units and associated harm-reduction equipment on annual or recurring bases, with delivery schedules tied to community health operations rather than episodic emergency stockpiling. State and local health departments and county public health agencies are the primary issuing bodies, soliciting through competitive bidding processes that require vendors to meet standard compliance certifications including drug-free workplace status, E-Verify authorization, and appropriate insurance coverage.

Recent activity centers on the Southeast, where Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023. Texas HHS Commission posted a Request for Information (RFI HHS0017013) on April 3, 2026, exploring vendor capacity for direct-to-manufacturer prescription fulfillment programs that would support pharmacy benefit operations across state employee and retiree plans—a broader strategic inquiry rather than a direct naloxone procurement but signaling state-level interest in streamlining drug acquisition and dispensing channels. The code shows limited recent concentrated activity; most opportunities appear to originate from county and regional health authorities rather than statewide coordinated purchasing, and no evidence of cooperative purchasing vehicles or standing master agreements under this specific commodity code is present in the source.